Neville Rodie & Shaw Inc. Trims Holdings in Zoetis Inc (ZTS)

Neville Rodie & Shaw Inc. reduced its holdings in shares of Zoetis Inc (NYSE:ZTS) by 1.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 152,993 shares of the company’s stock after selling 1,494 shares during the period. Zoetis comprises 1.4% of Neville Rodie & Shaw Inc.’s portfolio, making the stock its 19th largest holding. Neville Rodie & Shaw Inc.’s holdings in Zoetis were worth $14,008,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ZTS. Amundi Pioneer Asset Management Inc. increased its stake in shares of Zoetis by 319.9% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock worth $231,187,000 after purchasing an additional 2,109,036 shares in the last quarter. Banque Pictet & Cie SA increased its stake in shares of Zoetis by 5,516.1% in the second quarter. Banque Pictet & Cie SA now owns 1,679,617 shares of the company’s stock worth $143,087,000 after purchasing an additional 1,649,710 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Zoetis by 22.3% in the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock worth $460,890,000 after purchasing an additional 985,586 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Zoetis by 190.7% in the second quarter. Bank of Montreal Can now owns 1,327,357 shares of the company’s stock worth $113,078,000 after purchasing an additional 870,807 shares in the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of Zoetis by 97.7% in the second quarter. New York State Teachers Retirement System now owns 1,543,772 shares of the company’s stock worth $130,202,000 after purchasing an additional 762,828 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

In other Zoetis news, insider Kristin C. Peck sold 5,000 shares of the stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total transaction of $431,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Juan Ramon Alaix sold 135,000 shares of the stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total transaction of $12,359,250.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 213,467 shares of company stock valued at $19,502,725. 0.35% of the stock is owned by company insiders.

Shares of NYSE:ZTS traded up $0.27 during midday trading on Tuesday, reaching $91.74. 16,716 shares of the company were exchanged, compared to its average volume of 2,536,913. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38. Zoetis Inc has a one year low of $63.03 and a one year high of $94.31. The firm has a market cap of $44.12 billion, a price-to-earnings ratio of 38.08, a P/E/G ratio of 1.74 and a beta of 1.01.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same quarter in the prior year, the business earned $0.53 earnings per share. Zoetis’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, research analysts predict that Zoetis Inc will post 3.07 earnings per share for the current year.

ZTS has been the subject of a number of analyst reports. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective for the company. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a research note on Monday, September 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $98.00 price objective on shares of Zoetis in a research note on Monday, October 1st. Argus increased their price objective on shares of Zoetis from $90.00 to $103.00 and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Finally, Jefferies Financial Group set a $96.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, July 13th. Eight research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Zoetis has a consensus rating of “Buy” and an average price target of $91.73.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: What are the risks of holding treasury bonds?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply